Piper Jaffray vice president and senior research analyst Danielle Brill, Pharm.D. just began coverage of GW Pharmaceuticals Plc. (NASDAQ:GWPH) alongside a ‘Buy’ rating and a price target of $180 USD per share.
Prior to joining Piper Jaffray in 2018, Brill spent three years at Needham and Company, where she also covered biotechnology and biopharmaceuticals. Before her career on Wall Street, Brill worked as a clinical pharmacist at Mount Sinai Hospital in New York City. She also worked in research laboratories focused on the development of novel therapeutics for lymphoid malignancies at Columbia Presbyterian and NYU Langone.
Based on a last-traded price of $142.81 USD for shares of GWPH on the NASDAQ, Brill’s price target represents approximately 26% of potential upside.
We’ll continue to monitor analyst activity and in the meantime, be sure to subscribe to Cannabis Biotech Updates here and Cannabis Stock Updates here so you never miss an important update. For GW-specific updates, be sure to subscribe to GW Pharma Updates here.
Get Real-Time Updates from MJobserver.com